GW Pharmaceuticals Limited, a pioneering biopharmaceutical company headquartered in Great Britain, has established itself as a leader in the cannabis-based medicine industry. Founded in 1998, the company has made significant strides in developing innovative therapies derived from cannabis, particularly for neurological conditions. With a strong focus on research and development, GW Pharmaceuticals is renowned for its flagship product, Epidiolex, the first FDA-approved cannabidiol (CBD) medication for epilepsy. This groundbreaking achievement underscores the company's commitment to advancing cannabinoid science and improving patient outcomes. Operating primarily in Europe and North America, GW Pharmaceuticals has garnered a notable market position, recognised for its rigorous clinical trials and regulatory compliance. As the industry evolves, GW continues to set benchmarks in the therapeutic use of cannabis, solidifying its reputation as a trusted name in the biopharmaceutical sector.
We don't have data for GW Pharmaceuticals Limited, but we can show you information about their parent organization instead.
View parent company